第四章 血浆脂蛋白及其代谢紊乱 (plasma lipoproteins and its metabolic disorder)

Click here to load reader

Upload: linda-welch

Post on 03-Jan-2016

244 views

Category:

Documents


7 download

DESCRIPTION

第四章 血浆脂蛋白及其代谢紊乱 (Plasma Lipoproteins and Its Metabolic Disorder). 长沙医学院 李子博. 主要内容. 一、血浆脂蛋白及其代谢. 二、脂蛋白代谢紊乱. 三、脂蛋白代谢紊乱与 AS. 四、高脂蛋白血症的预防和治疗. 五、脂蛋白和脂质测定.  第一节 血浆脂蛋白. 一、血浆脂蛋白定义. 二、血浆脂蛋白基本结构. 三、血浆脂蛋白分类. 四、血浆脂蛋白特征. 分布:脂库 储存脂(可变脂). 甘油三酯. triacylglycerol. 脂类. lipids. 分布:各种生物膜 - PowerPoint PPT Presentation

TRANSCRIPT

  • (Plasma Lipoproteins and Its Metabolic Disorder)

  • AS

  • lipidstriacylglycerollipoid

  • (TC) (FC) (CE) (PL)(TG)(FFA)

    :4.07.0g/L

  • ( lipoprotein, LP) . +

  • :CETGPLFCFCPL

  • ,

  • CMVLDLIDLLDLHDLLp(a)----TG(80-90%)TG(50-70%)TGCEChCE(40-50%)PLCEPLAIB48CCCB100ECCCB100EB100AIA(a)B100 TGTGTGCECECE

  • LpaLPa 1LDL(TC) Apo B100Apo 2Lp()Apo(a)Apo(a) LDL 3Lp()LDL 4Apoa

  • Lpa 1Lp(a) 2Lp(a)0.2-0.3g/L 0.30 g/LAS2LDL-C CHD5LPa CHD 3Lp(a)CHDLpa 4Lpa

  • (apolipoproteinApo) 1972AlaupovicApoABCDEFGHJ

  • 123

  • 1ApoAB(a)Apo ,/

  • ApoEApoC ApoCII

    19q111q2 2 , , ,ApoCApoAApoAApoA

  • LDLVLDL

  • ,

  • LDL836 36 115kD, LDLR LDL (LDLR)

  • 1 ApoB100ApoEApoB-E ApoB48 LDLApoB100VLDL-VLDL 2

  • -VLDLVLDL -LP CEApoApoEApoCVLDL

  • ApoB/ELDL43 LDLApoB100LDLLDL LDL6570LDLR

  • LDLApoB100ELDL

    LDLR

  • l 2 3 4 5 6 7 LDL LDLRLDLR LDLLDL: CECh+FFA TGFFA ApoBAA LDL

  • : FC HMGCoA LDLRLDLRLDLLDLR ACATChCE

  • LDLLDL 5

  • VLDLRLDLRLDLR,5552193246 1

  • VLDLRApoE(VLDL-VLDLVLDL)LDL

    2

  • VLDL-VLDL LDLR VLDLRVLDL-VLDL VLDLVLDLVLDL VLDLR 3

  • SR-A(SR-A6I:scavenger receptor, SR SR:SR-A-B-C-D-E -F

  • SR LDL () () LDL

  • : LPLHLLCATHMGCoAase: CETP LPL LCAT HMGCoAaseHL(HTGL)

  • LPL 60kD LPLLPL ApoC

  • 1CMVLDLTG 2PL 3PLApoCh 4CM

  • /HL/HTGL 53kD: ApoC

  • : 1.VLDL-VLDLTG 2HDL3HDL2 3. HDL

  • LCAT: HDL41663kD

    : Apo AI

  • 1. ()HDLFCCECEHDL FC CE 2. ChCh

  • CoA HMG CoA

  • CETP: 74ku

    CETPHDLCEHDL-c

  • CMCM

    VLDLIDL LDL HDL HDL

  • (TG)FFAMGTGPL TGTCPLApoB48ApoAICM

  • HDL (ApoC,E) CM() CM (TG) LPL MG+FFA

    CMLPLCM CM CMTG

  • TGApoB100CEVLDLVLDL VLDL:TGVLDL

  • LDLVLDLCEHDL(CETP LDL

  • HDL2CETPVLDLLDLCETGVLDLLDLFC HDL(RCT) ()HDL HDLHDLn,PLApoA,HDLHDLHDL3CE HDL2

  • TCTG CMVLDLLDLHDL

  • :

  • 1967Fredrickson:

    1970(WHO)

    WHO

  • 1()412h()?

    2TGTC

    3LP()LP(%)(?)

  • 1 ( ) TG TC TC/TG0.2 CM () 10 () ICM

  • 2LPLApoC TG TG Apo C() LPL CMTG CMCM CM

  • 1 TCTG TC/TG1.6;LDL -LP AS AS () IIa()

  • 2LDL (1) LDL LDL LDL(1/2) (2) LDLLDL (3) LDLLDL LDL LDLLDL-ChAS

  • 1 ;TG,TC, TC/TG>1.0LDLVLDL(- LP -LP) ,AS 2ApoB100VLDL LDL () b-LP-LP

  • 1 ; TG,TC IDL-LP (-LP-LP )-VLDL AS() (-VLDL- )

  • 2 ApoE ApoEApoE2E3E4ApoE(LDL)E2LDLApoE3/E3LDLApoE2/E2LDLLDL

  • 1 TGTCTC/TG 0.6-1.6 VLDL-LP AS 2 VLDL/VLDL () (TGVLDL)

  • 1 () TGTCTC/TG 0.6 CM-LP 20 2 ApoCLPLLPL CMVLDLTG() (CM-LP)

  • TG4:(1)CMVLDLI(2)CMVLDLV(3)4VLDLTC TCIIIIIbTC(4)IIa

  • CETPHTGL HDL

    HDL HDL-C2.6mmol/LHDLCETPHTGLHDL

  • AS AS HDLAS

  • ASASAS

  • LDL-VLDL oxLDLAS HDLAS AS

  • CMVLDLLPLCMIDLApoE -VLDL(ApoE)-VLDLASAS

  • LDL LDLLDLLDL,LDL: LDL LDL LDL LDLApoB100LDLLDLAS

  • LDL-CAS LDLAB: B(LDL)AS,BLDL,LDLLDLCHD LDL(SD-LDL) BLDL

  • LP(a) 0l000mg/LApo(a),Apo(a), 37Kringle-4(K-4),1Kringle-5(K5)1(a) Lp(a) Kringle(3)

  • LDL HDLAS

  • HDL: : NCEHCEFCHDLNCEH FC: NCEH NCEH

  • TG HDL-C X

  • (deadly quartet) Kaplan

  • IDF IDF

  • 2002(NCEP)ATP III 33 >102cm >88cm 150mg/dL1.69mmol/L) HDL-C < 40 mg/ dL1.04mmol/L) < 50 mg/dL(1.29mmol/L) 110mg/dL (6.1mmol/L) 130/85 mmHg

  • 2004 (CDS) 53 85 cm ; 80 cm ) SBP130mmHg / DBP85 mmHg 150mg/dL < 40 mg/ dL 110mg/dL

  • ASAS : TCTGLDL HDL AS

  • 1997: ()

  • (mmol/L1997)

    TCTGLDL-CHDL-C

  • (mmol/L)

    AS() TC>5.70>6.213.64>4.145.703.10>3.644.70>5.202.60>3.10

  • 1993ATP: LDL-C 3.36mmol/L HDL-C 0.9mmol/L 82001ATP LDL-C 2.6mmol/L HDL-C 1.0mmol/L LDL-CAS LDL-C2.6mmol/L ()

  • LDL-CHDL-CTCATP(mmol/L)

    LDL-CTCHDL-C

  • CHDVLDL-CVLDL()VLDL-C TG4 1.7mmol/L 1.7 2.25mmol/L 2.26 5.64mmol/L 5.65mmol/L

  • / ASAS

  • CE70FC30

    :

    1

  • 1

  • (2) 70

  • 2.85.2mmol/L
  • TCTCTC TC TC

  • TG: 2 TG

  • 11 2KOH 3 4(45--27-)(NH4+)

  • 2 TGTGGKGOD

  • 0.561.70mmol/L 0.361.50mmol/L

    1.70mmol/L (150mg/dl)

  • TGTG TG

  • 3 (PL)PL : , 1.33.2mmol/L

  • Cl0(FFA) : (C18:1)54 (C16:1)34 (C18:1)6 (C22:0)(C14:0)(C20:1) FFA12min 4

  • FFA: FFA,: 424h30

    : 0.40.9mmol/L

  • :24h() 4831

    24mol/L 4.140.78mol/L 3.970.77mol/L 5

  • () 1 (ultracentrifugation method)

  • 2(electrophoresis Method (TGTC) 12hCM

  • 4 16h24h: CM,VLDL LDL 3

  • HDL-C 0.9mmol/L LDL-C 2.13.1mmol/L 2.8mmol/L4

  • () +

    (1) (precipitate method)

  • PEG2000LDL+VLDL () HDL()HDL-C

    HDL+VLDL () LDL()LDL-C

  • (2)

    (pH)

  • HDL-CHDL-C0.9 mmol/L HDL-C1.55mmol/L HDL-CTGHDL-CHDL-CHDL-CHDL-CHDL-C 0.9mmol/L

  • LDL-C TCTGHDL-CLDL-CFriedewald1972 LDL-C=TC[HDL-C+(TG1/5)] CM TG4.60mmol/L

  • 2.1 3.1mmol/L 2.8mmol/L

  • LDL-CTCHDL-CLDL-CTCLDL-C

  • Lp(a)-C : Lp(a)01000mg/L 300mg/LLp(a):

  • ApoApo (1) sApoAApoB100Apoa (2) ApoAangier ApoC

  • ApoHDLCLDL , Apo AI Apo B100, , , Apo AI Apo B100 ApoINAITA

  • ApoAIHDL ApoBLDLApoAIApoBHDLLDL ApoAIHDLApoBLDLHDLLDLApoAIApoBApoAIApoB

  • 135 2LDL-CHDL-C1214

  • 3441-3

  • 5 (1) 31730 (2)

  • (3) 24LDL-C12-2411224

  • (4) 510min10-15min9-10

  • 1.2 2.24h 3. 4.TCTCTG12h 5.5min

  • CDC 6.1min 7.EDTA2-81.03 8.24h41-20-70

  • NCEP-ATPTCTGHDL-CLDL-CapoAIapoBLp(a)